In line, a phase I trial is recruiting patients with KRAS+ metastatic pancreatic cancer to study the best dose of hydroxychloroquine when given together with the MEK1/2 inhibitor binimetinib (NCT04132505). Here, KRAS is linked to familial pancreatic carcinoma.